Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Fixed Combination Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension and Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Trial Profile

Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Fixed Combination Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension and Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2016

At a glance

  • Drugs Brimonidine/brinzolamide (Primary) ; Brimonidine; Brinzolamide
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 28 Jul 2014 Brinzolamide/brimonidine [Simbrinza] has been approved in the EU based on data from this trial and another pivotal phase III trial, according to a Novartis media release.
    • 28 May 2014 New source identified and integrated, European Clinical Trials Database record (EudraCT2010-024512-34).
    • 28 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top